13,452 Shares in Nanobiotix S.A. (NASDAQ:NBTX) Purchased by Millennium Management LLC

Millennium Management LLC bought a new position in shares of Nanobiotix S.A. (NASDAQ:NBTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,452 shares of the company’s stock, valued at approximately $39,000.

A number of other hedge funds also recently bought and sold shares of the business. OLD Mission Capital LLC purchased a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $139,000. Jane Street Group LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $73,000. Finally, Geode Capital Management LLC purchased a new position in Nanobiotix in the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Analyst Upgrades and Downgrades

NBTX has been the subject of a number of recent analyst reports. Guggenheim cut their price objective on Nanobiotix from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, April 4th. UBS Group raised shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Stock Performance

NBTX opened at $5.15 on Friday. Nanobiotix S.A. has a 52 week low of $2.76 and a 52 week high of $6.00. The business has a fifty day simple moving average of $3.76 and a 200-day simple moving average of $3.49.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.